Ads
related to: Takeda Pharmaceuticals Co Ltd- Approved Medicines
See the Approved Treatments
Using Our Antibody Science.
- Sign Up
Sign Up for Updates, News
and Much More.
- About Us
Discover the Unique Approach
That Makes Genmab Different.
- Antibody Science
Explore Our Unique Platforms
For Creating Antibody Treatments.
- Approved Medicines
Search results
Takeda To Add Mid-Stage Autoimmune Disease Candidate For $4B
Benzinga via Yahoo Finance· 1 year agoTakeda Pharmaceutical Co Ltd (NYSE: TAK) will acquire NDI-034858 from Nimbus Therapeutics, an oral,...
Takeda's Approved Blood Cancer Drug Hits Primary Goal In Newly-Diagnosed Patient Settings
Benzinga via Yahoo Finance· 1 year agoTakeda Pharmaceutical Co Ltd's (NYSE: TAK) Phase 3 PhALLCON trial of Iclusig (ponatinib) met its...
Takeda Reports 13% Fall In Nine Month Operating Profit, Keeps Annual Guidance Unchanged
Benzinga via Yahoo Finance· 1 year agoTakeda Pharmaceutical Co Ltd (NYSE: TAK) reported a 13% drop in operating earnings to ¥401.9 billion...
Takeda's FY22 Net Profit Jumps 38%, But Expects Lower FY23 Revenues
Benzinga via Yahoo Finance· 11 months agoTakeda Pharmaceutical Co Ltd's (NYSE: TAK) FY22 net profit rose 37.8% to ¥317.02 billion, mainly due...
Takeda's Highest Dose Psoriasis Candidate Can Potentially Beat Bristol Myers' Approved Drug, Analyst...
Benzinga via Yahoo Finance· 1 year agoTakeda Pharmaceutical Co Ltd (NYSE: TAK) announced results from a Phase 2b clinical trial of TAK-279...
Takeda Posts Lower 1H Profit, Lifts FY22 Outlook
Benzinga via Yahoo Finance· 1 year agoTakeda Pharmaceutical Co Ltd's (NYSE: TAK) first-half net profit declined 9.2% from the prior year to ¥166.8 billion. Earnings per share fell 8.1% to...
Takeda Presents Vedolizumab Data For Preventing Graft-Versus-Host Disease In Stem Cell Transplant...
Benzinga via Yahoo Finance· 1 year agoTakeda Pharmaceutical Co Ltd (NYSE: TAK) announced late-breaking data from the Phase 3 GRAPHITE...
Arrowhead Pharmaceuticals Reports Underwhelming Data From Inherited Disease Study
Benzinga via Yahoo Finance· 1 year agoTakeda Pharmaceutical Co Ltd (NYSE: TAK) and Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) announced...
Takeda Moves Out From Licensing Agreement With Theravance Biopharma
Benzinga via Yahoo Finance· 11 months agoIn its Q1 earnings release, Takeda Pharmaceutical Co Ltd (NYSE: TAK) said it agreed to discontinue...
With Approval For Dengue Vaccine, Takeda May Find It Challenging To Compete Bigger Rivals: Report
Benzinga via Yahoo Finance· 2 years agoLast week, Takeda Pharmaceutical Co Ltd's (NYSE: TAK) dengue vaccine, Qdenga, was approved in...